Active, not recruitingPHASE1, PHASE2NCT04145349

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Studying Desmoplastic small round cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eli Lilly and Company
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Intervention
Ramucirumab(drug)
Enrollment
30 enrolled
Eligibility
29 years · All sexes
Timeline
20202026

Study locations (22)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04145349 on ClinicalTrials.gov

Other trials for Desmoplastic small round cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Desmoplastic small round cell tumor

← Back to all trials